Meeting
2020 ASCO Virtual Scientific Program
Is there a benefit of oxaliplatin in neoadjuvant treatment of locally advanced rectal cancer? An updated meta-analysis.
Authors
Gaetan Des Guetz
CH Delafontaine, St Denis, France
Gaetan Des Guetz , Thierry Landre , Anne Larrouy , Yves Panis , Jean F. Morere , Muriel Mathonnet , Laurent Quero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4098)
DOI
10.1200/JCO.2020.38.15_suppl.4098
Abstract #
4098
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.
First Author: Hans-Joachim Schmoll
Poster
2013 Gastrointestinal Cancers Symposium
Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer.
First Author: Junichi Hasegawa
Poster
2013 Gastrointestinal Cancers Symposium
Oxaliplatin and capecitabine initially concomitant to radiotherapy then administered in the resting period in high-risk locally advanced rectal cancer.
First Author: Pei-Rong Ding
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Toxicities and outcomes of neoadjuvant treatment in elderly patients with locally advanced rectal cancer: A scoping review.
First Author: Ruba Ahmed Mohammed Hamed